World Library  
Flag as Inappropriate
Email this Article

Mipomersen

Article Id: WHEBN0018978054
Reproduction Date:

Title: Mipomersen  
Author: World Heritage Encyclopedia
Language: English
Subject: Hypolipidemic agent, ATC code C10
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Mipomersen

Mipomersen (previously ISIS 301012, trade name Kynamro) is a cholesterol-reducing drug candidate. It is an antisense therapeutic that targets the messenger RNA for apolipoprotein B.[1][2][3] It is administered as a weekly injection.

Structure

The compound is a 'second-generation' antisense oligonucleotide; the nucleotides are linked with phosphorothioate linkages rather than the phosphodiester linkages of RNA and DNA, and the sugar parts are deoxyribose in the middle part of the molecule and 2'-O-methoxyethyl-modified ribose at the two ends. These modifications make the drug resistant to degradation by nucleases, allowing it to be administered weekly. The drug accumulates in the liver, which is convenient since apolipoprotein B predominantly acts there.

The complete sequence is

G*-C*-C*-U*-C*-dA-dG-dT-dC-dT-dG-dmC-dT-dT-dmC-G*-C*-A*-C*-C* [d = 2'-deoxy, * = 2'-O-(2-methoxyethyl)]

with 3'→5' phosphorothioate linkages.[4]


Clinical development

The drug was discovered and developed to Phase 2 POC by ISIS Pharmaceuticals and subsequently licensed to Genzyme Corporation in an auction-style licensing bid. Isis earned an upfront payment of $325 million, with payments of a further $825 million if certain milestones are met. The licensing deal closed in June 2008.[5]

Mipomersen completed two separate phase-3 trials with two more Phase 3 trials to be presented in mid-2010.

The two completed Phase 3 trials were in patients with familial hypercholesterolemia (FH), both homozygous (ho)[6] and heterozygous (he).[7] FH is a genetic disorder that causes exceptionally high levels of low-density lipoprotein cholesterol. Both trials showed exceptional performance with the highest efficacy seen so far in those two patient populations, and with relatively low drop-out rates compared to other injectable drugs. Both of these trials also demonstrated the continued manageable safety and tolerability profile of mipomersen.

The remaining Phase 3 studies are due to be presented shortly (mid-2010) and include patients at high risk (HR) or who are severe hypercholesterolemic (SH).

August 2010: Third and fourth phase 3 trials were stated to have met primary and secondary endpoints.[8]

Genzyme plans to file for the first indication in the first half of 2011 in both the US and EU for hoFH & SH. Subsequently Genzyme plans on filing in the EU only for heFH as the FDA is requesting an outcome study be performed for any indication beyond the first.

Mipomersen is a synthetic molecule and launch quantities will be manufactured by Isis at their Carlsbad manufacturing facilities, and fill & finish will be performed at a third party facility.

In addition to the Phase 3 program, mipomersen has been tested in statin-intolerant patients in a small Phase 2 study.[9] Also, alternative dosing regimens of mipomersen are being tested in Phase 1 studies. The alternative dosing regimen studies are to address long term patient and physician convenience for administering the drug. The drug, if approved, will be provided in a small size needle syringe and can be self-injected by patients. The needle is only one gauge larger than that of insulin making it possibly acceptable and tolerable from the patient's perspective by decreasing the pain of injection. The inconvenience factor of injecting the medication, as opposed to swallowing a pill will likely factor in potentially treating high and moderate risk populations.

In January 2013, The United States Food and Drug Administration approved mipomersen for the treatment of homozygous familial hypercholesterolemia.[10][11]

References

External links

  • Phase III trials of Mipomersen
  • Phase 3 results from Isis Pharmaceuticals
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.